• Event

    What is up for biopharmaceutical policy in 2024?

    Incubate and DLA Piper invite you to join us on the morning of Sunday, January 7th, as part of JPM Week 2024.

  • Blog

    Mary R. Grealy on the Small Molecule Penalty, U.S. Dominance in Life Sciences, and More

    Incubate Executive Director John Stanford sat down this week with Mary R. Grealy, CEO of the Healthcare Leadership Council, to discuss the latest developments in health policy on the Making Medicine podcast.

  • Statement

    Incubate releases statement on Fitch Ratings’ analysis of Medicare drug price negotiations

    Fitch Ratings recently released an analysis showing that Medicare's drug price negotiation program is expected to deter investments into small molecule drugs.

  • Blog

    Medicare presses forward with drug price setting

    In late August, the Centers for Medicare & Medicaid Services announced the first 10 drugs that will be subject to Medicare price setting under last year's Inflation Reduction Act.

  • Blog

    Mohit Manrao Talks Small-Molecule Penalty, Eliminating Cancer as a Cause of Death, and More

    The small-molecule penalty "doesn't create the right incentives for where we want to go with the Cancer Moonshot or driving cures," Mohit reflected.

  • Statement

    Incubate releases video explainer on small molecule penalty

    Incubate released a video explaining how the small molecule penalty in recently passed legislation will negatively impact medical research and innovation.

  • Statement

    Life sciences investors react to first 10 drugs selected for government price controls

    Executive Director John Stanford issued a statement in response.

  • Comment

    Incubate Comment in Response to NIH Technology Transfer Workshop

    Incubate submitted this comment on August 18, 2023.

  • Statement

    New legislation would spread the disease of price controls to more treatments and cures

    Incubate Coalition executive director John Stanford issued the following statement in response to the introduction of the Lowering Drug Costs for American Families Act:

  • Comment

    Incubate Submits Comment in Response to Draft Legislation to Reauthorize PAHPA

    Incubate recently submitted comment in response to the Senate HELP Committee’s draft legislation to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA).

  • Statement

    CMS’ Final Guidance on Medicare Drug Price Negotiation Program Offers Some Clarity, But Misses Opportunity to Address the Small Molecule Penalty

    Executive Director of Incubate, John Stanford, issued the following statement regarding the release of the Centers for Medicare and Medicaid Services’ (CMS) final guidance on the Medicare Drug Price Negotiation Program.